Research

Hormonal

Tirzepatide, a GIP/GLP-1 receptor agonist, achieves unprecedented reductions in HbA1c and clinically significant weight loss in Type 2 Diabetes patients, with a substantial proportion achieving normoglycemia without hypoglycemia.

Tirzepatide is a once-weekly injection that significantly lowers blood sugar and promotes substantial weight loss in people with Type 2 Diabetes, often without causing low blood sugar. It is designed to be started at a low dose and gradually increased to minimize side effects like nausea. This treatment challenges the old view that effective diabetes management requires insulin or causes weight gain.

GoodSupportsHIGH confidence
In the SURPASS clinical trial program in type 2 diabetes mellitus (T2D), tirzepatide was associated with unprecedented reductions in HbA1c, clinically significant weight loss and other metabolic benefits, combined with low rates of hypoglycaemia across a wide range of patient characteristics.
Richard J. MacIsaac et al. · Diabetes Therapy · 2023

Why this rating

Based on multiple phase 3 randomized controlled trials (SURPASS-1 to 5) with large sample sizes and diverse populations.

Source

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin

Richard J. MacIsaac et al. · Diabetes Therapy · 2023

DOI 10.1007/s13300-023-01475-5

narrative_reviewCited 14×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →